Pharma BD Deal Intelligence

Cassava Sciences, Inc. / Yale University

2025 · Licensing/Option · $4M · Complete

On February 26, 2025 Cassava Sciences entered a license agreement with Yale University granting Cassava exclusive worldwide rights, with sublicensing rights, to Yale's interest in patents and other intellectual property relevant to developing and commercializing simufilam for Tuberous Sclerosis Complex (TSC)-related epilepsy and other potential indications. Cassava pays a nominal upfront license fee, milestone payments totaling up to $4.5 million, a low-to-mid double digit share of any priority review voucher transfer consideration, and tiered low-to-mid single digit royalties on net sales subject to tiered minimum annual royalties.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals